IPO consultation on experimental use and Bolar exemption
29 July 2011
The IP Federation has responded to the IPO consultation with deadline 31 July 2011.
We strongly support any change to the law that will improve the current UK regulatory framework by removing the risk of patent infringement when carrying out clinical and field trials involving pharmaceuticals. The ultimate aim should be to harmonise law throughout the EU in this area, but until this happens we advocate changing the UK patent law unilaterally to exempt from infringement all activities relating to regulatory approval of a drug product.
For full details, click HERE.
To see all our policy papers, click HERE.
IP Federation Annual Lunch
In AD 1611, a set of scholars sat in Stationers’ Hall, a stone’s...
Third party observations at the EPO
The IP Federation has written to the EPO asking it to reconsider its decision...
Cabinet Office Procurement Policy – Use of Open Standards
The IP Federation has submitted a response to Government proposals that open...
Independent Review of IP and Growth
The final report on the Independent Review of IP and Growth chaired by Professor...
Commission report on implementation of enforcement directive
The IP Federation has submitted a policy paper on the enforcement of intellectual...
IPO consultation on amending the Patents Act 1977 to provide for online patent document inspection
The IP Federation has submitted a response to the Intellectual Property Office's...
IP Federation supports EU patent reform
The President of the IP Federation has written to Baroness Wilcox, Parliamentary...
IP Federation supports use of credit cards for payment of fees at the IPO
The President of the IP Federation has written to John Alty, Chief Executive...
Development of a PCT third party observations system
The IP Federation has submitted a response to WIPO proposals as to...
Unintentional infringement of UK and Community designs
The IP Federation has submitted a response to the IPO public Consultation...